These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Shankar S; Ganapathy S; Srivastava RK Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980 [TBL] [Abstract][Full Text] [Related]
8. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Shankar S; Chen Q; Ganapathy S; Singh KP; Srivastava RK Mol Cancer Ther; 2008 Aug; 7(8):2328-38. PubMed ID: 18723480 [TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria. Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592 [TBL] [Abstract][Full Text] [Related]
10. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Ng CP; Zisman A; Bonavida B Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140 [TBL] [Abstract][Full Text] [Related]
11. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. Huerta-Yepez S; Vega M; Jazirehi A; Garban H; Hongo F; Cheng G; Bonavida B Oncogene; 2004 Jun; 23(29):4993-5003. PubMed ID: 15048072 [TBL] [Abstract][Full Text] [Related]
12. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934 [TBL] [Abstract][Full Text] [Related]
13. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Shankar S; Singh TR; Srivastava RK Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092 [TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Johnson TR; Stone K; Nikrad M; Yeh T; Zong WX; Thompson CB; Nesterov A; Kraft AS Oncogene; 2003 Aug; 22(32):4953-63. PubMed ID: 12902978 [TBL] [Abstract][Full Text] [Related]
15. Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Fulda S; Debatin KM Eur J Cancer; 2005 Mar; 41(5):786-98. PubMed ID: 15763656 [TBL] [Abstract][Full Text] [Related]
16. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296 [TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775 [TBL] [Abstract][Full Text] [Related]
18. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Yamaguchi H; Bhalla K; Wang HG Cancer Res; 2003 Apr; 63(7):1483-9. PubMed ID: 12670894 [TBL] [Abstract][Full Text] [Related]
19. Resveratrol sensitizes lung cancer cell to TRAIL by p53 independent and suppression of Akt/NF-κB signaling. Rasheduzzaman M; Jeong JK; Park SY Life Sci; 2018 Sep; 208():208-220. PubMed ID: 30031063 [TBL] [Abstract][Full Text] [Related]
20. Phytosphingosine in combination with TRAIL sensitizes cancer cells to TRAIL through synergistic up-regulation of DR4 and DR5. Choi SY; Kim MJ; Chung HY; Lee SJ; Jang YJ Oncol Rep; 2007 Jan; 17(1):175-84. PubMed ID: 17143496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]